FDA Requires New Vision-Loss Warning for GLP-1 Drugs Wegovy and Zepbound
The FDA identified a potential increased risk of NAION among GLP-1 receptor agonist users and is requiring labeling updates for the drug class.
By StoryBreak
Published November 10, 2026 at 8:02 AM EST

The Food and Drug Administration has identified a potential increased risk of non-arteritic anterior ischemic optic neuropathy, or NAION, among people who use GLP-1 receptor agonists.
The agency is requiring the labels for GLP-1 receptor agonists to include information about NAION in the Warnings and Precautions section. The labeling change applies to the medications covered by the FDA’s action.
NAION can cause sudden, painless loss of vision in one eye. The condition can also result in permanent vision loss.
The FDA’s analysis examined 126 clinical trials. Among GLP-1 users, the analysis found 6.4 NAION cases for every 100,000 person-years. The comparison groups recorded 3.8 cases for every 100,000 person-years.
Wegovy is a GLP-1 receptor agonist that contains semaglutide and received FDA approval in 2021. Zepbound contains tirzepatide and received FDA approval in 2023.
The FDA’s finding concerns a potential risk associated with GLP-1 receptor agonist use. The required labeling change places information about that condition in a section intended to identify risks and precautions for patients and health professionals.
The agency’s analysis provides the numerical comparison between GLP-1 users and comparator groups, while the labeling requirement establishes how the NAION information must appear on the products’ labels.
Related coverage: GLP-1 Vision-Loss Lawsuits Grow as Scientists Debate Whether Ozempic Causes NAION
Sources & Further Reading
StoryBreak
Independent digital news and reporting, updated throughout the day.
This article was researched and drafted with AI assistance and reviewed as part of StoryBreak's editorial process before publication. Read our editorial standards.




